

To the Commissioner for Patents:

This is a request for filing a ☒ continuation ☐ divisional ☐ continuation-in-part application, under 37 CFR 1.53(b), of pending prior application Serial No. 08/182,183 filed on May 23, 19 94, of Leu-Fen H. Lin, et al.

for Nucleic Acids Encoding Glial Cell Line-Derived Neurotrophic Factor (GDNF) (As Amended)

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. ☒ Transmitted herewith are:
 - ☒ 105 pages of specification, 11 pages of claim(s) and 1 page of abstract, **totaling** 117 pages.
 - ☒ 31 sheet(s) of drawings.
 - ☒ 3 pages of Oath or Declaration by the applicant(s):
 - ☐ a. Newly executed (original or copy)
 - ☒ b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional applns. only)
 - ☒ 19 pages of **Replacement** Sequence Listing and 1 page Attorney's Statement Pursuant to 37 CFR 1.821(e)
2. ☒ The filing fee is calculated below:

For	Number Filed		Number Extra		Rate		Fee
Total Claims	1	- 20 =	0	x	\$18.00	=	\$ 0.00
Independent Claims	1	- 3 =	0	x	\$86.00	=	0.00
Multiple Dependent Claims	0			+	\$290.00	=	0.00
Basic Fee					\$770.00	=	770.00
Total Filing Fee							\$ 770.00

3. ☒ Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$ 770.00. An original and one copy are enclosed.
4. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
5. ☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.
6. ☒ Cancel in this application original claims 1-25 and 27-74 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EL360692085US

Date of Deposit: January 14, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

St. Andrew
Printed Name

St. Andrew
Signature

7. ☒ Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a ☒ continuation ☐ division of application Serial No. 08/182,183, filed May 23, 1994, now pending, which is a 371 National Phase filing of PCT Application No. US 92/07888, filed September 17, 1992, which claims priority to 07/764,685, filed September 20, 1991, now abandoned, which is/are hereby incorporated by reference.--

8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. ☒ New formal drawings are enclosed.

9. ☐ Priority of application Serial No. _____ filed on _____ in _____ (country) is claimed under 35 USC 119.

9a. ☐ The certified copy has been filed in prior application Serial No. _____ filed _____

10. ☒ The prior application is assigned of record to Amgen Inc.

11. ☒ A preliminary amendment is enclosed.

12. ☒ Also enclosed Information Disclosure Statement including Forms 1449 (7 pgs)

13. ☐ Other: _____

14. ☒ The power of attorney in the prior application is to:
Steven Odre, Reg. No. 29,094, Ron K. Levy, Reg. No. 31,539, Daniel R. Curry, Reg. No. 32,727 (Now Retired),
Robert R. Sharp, Reg. No. 45,609, and Barry J. Swanson, Reg. No. 33,215.


a. ☒ The power appears in the original papers in the prior application.

b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

c. ☒ Address all future communications to
Robert L. Sharp
 at the address below.

Signator: ☐ Assignee of complete interest

☒ Attorney or agent of record


 Robert L. Sharp
 Attorney/Agent for Applicant(s)
 Registration No. 45,609
 Phone: (805) 447-5992
 Date: January 14, 2004

Please send all future correspondence to:
 U. S. Patent Operations/RLS
 Dept. 4300, M/S 27-4-A
 AMGEN, INC.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1799, USA

21069

21069

PATENT TRADEMARK OFFICE